Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.44 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | LOX | P28300 | 1/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1673906 | 0.82 | KDM4E (0.64) | KDM4EPKML3MBTL1NFE2L2SLC40A1 | |
| SCHEMBL29622864 | 0.78 | KDM4E (0.50) | KDM4EPKML3MBTL1NFE2L2SLC40A1 | |
| SCHEMBL323373 | 0.78 | KDM4E (0.50) | KDM4EPKML3MBTL1NFE2L2SLC40A1 | |
| SCHEMBL30016799 | 0.78 | KDM4E (0.50) | KDM4EPKML3MBTL1NFE2L2SLC40A1 | |
| SCHEMBL18606310 | 0.78 | KDM4E (0.50) | KDM4EPKML3MBTL1NFE2L2SLC40A1 | |
| SCHEMBL24214242 | 0.78 | KDM4E (0.50) | KDM4EPKML3MBTL1NFE2L2SLC40A1 | |
| SCHEMBL29757501 | 0.78 | KDM4E (0.50) | KDM4EPKML3MBTL1NFE2L2SLC40A1 | |
| SCHEMBL34548 | 0.78 | KDM4E (0.50) | KDM4EPKML3MBTL1NFE2L2SLC40A1 | |
| SCHEMBL23025 | 0.78 | KDM4E (0.55) | KDM4EPKML3MBTL1NFE2L2SLC40A1 | |
| SCHEMBL29569774 | 0.78 | KDM4E (0.50) | KDM4EPKML3MBTL1NFE2L2SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3957627-B1 | 6-MEMBERED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SHIONOGI & CO (JP) | 2024-06-19 | — | — | EP | disclosed |
| EP-4366733-A1 | TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF | LANDOS BIOPHARMA, INC. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11897899-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2024-02-13 | — | — | US | disclosed |
| EP-3927427-B1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | NIMMUNE BIOPHARMA INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230357744-A1 | ENGINEERED TRYPTOPHAN DECARBOXYLASES AND USES THEREOF FOR SYNTHESIZING TRYPTAMINE ANALOGS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-11-09 | — | — | US | disclosed |
| EP-3495363-B1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT | SHIONOGI & CO (JP) | 2023-08-23 | — | — | EP | disclosed |
| EP-4225315-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING INFLAMMATORY OR IMMUNE-MEDIATED CONDITIONS OF SURFACE TISSUES | Nimmune Biopharma, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4214200-A1 | LANCL LIGANDS | Nimmune Biopharma, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-113748109-B | Lanthionine C-like protein 2 ligands, cells prepared with said ligands and therapies using said ligands | 朗多生物制药股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116368133-A | NLRX1 ligand | 朗多生物制药股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| EP-1911759-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1832276-A1 | HAIR DYE COMPOSITION | Kao Corporation (JP) | 2007-09-12 | — | — | EP | disclosed |
| US-20070208059-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2007-09-06 | — | — | US | disclosed |
| EP-1735287-A1 | THERAPEUTIC AGENTS | Astrazeneca AB (SE) | 2006-12-27 | — | — | EP | disclosed |
| EP-1718617-A2 | 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005095354-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005080343-A2 | 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
| WO-1997003976-A1 | SEMICARBAZONE DERIVATIVES AND PESTICIDES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1997-02-06 | — | — | WO | disclosed |
| WO-1996010560-A1 | BENZAMIDE SEMICARBAZONE DERIVATIVES AND THEIR USE AS PESTICIDES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-11 | — | — | WO | disclosed |
| US-3966703-A | Asymmetrical frisazo dyestuffs derived from diazotized 2,7-diamino-carbazole | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897899-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | DRD3, DRD4, DRD2 | KDM4E 1725/4885PKM 4486/4885L3MBTL1 1935/4885 |
| US-20070208059-A1 | Therapeutic Agents | NLN, BDNF, GAP43 | KDM4E 3714/4885PKM 1427/4885L3MBTL1 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.